Indi Molecular Raises $1.5M For Antibody Startup

Culver City- and Seattle-based Indi Molecular, a startup developing a synthetic replacement for antibodies, has raised $1.5M in a seed funding round. The funding was led by InterWest Partners, and also included a number of un-named angel investors. Indi Molecular's technology is based on PCC (protein catalyzed capture) agent technology licensed from the California Institute of Technology. Caltech professor Jim Heath is a co-founder and board member of the startup, and the company has also licensed technology from the Scripps Research Institute. The funding is being used to spin Indi Molecular off from parent firm Integrated Diagnostics. More information »